A Van Hoof
Impact in
- Rheumatology top 10%
- Eosinophilic Disorders and Syndromes
-
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
Papers in
-
- Retinoids in leukemia and cellular processes 1
- Co-authors
- Peter Vandenberghe (2 shared papers)Danny Vanstraelen (1 shared paper)Marie Maerevoet (1 shared paper)A Hagemeijer (1 shared paper)Peter Marynen (1 shared paper)Lucienne Michaux (1 shared paper)Jan Cools (1 shared paper)D. Gary Gilliland (1 shared paper)
- Journals
- Annals of Oncology (1 paper)Leukemia (1 paper)Blood (1 paper)Molecular Cancer (1 paper)Journal of Cardiovascular Pharmacology (1 paper)
- Partner nations
- BelgiumNetherlandsItaly
In The Last Decade
A Van Hoof
9 papers receiving 210 citations
Peers
Comparison fields: 5 of 37
- Rheumatology 115
- Hematology 59
- Genetics 46
- Pulmonary and Respiratory Medicine 66
- Immunology 41
Countries citing papers authored by A Van Hoof
This map shows the geographic impact of A Van Hoof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A Van Hoof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A Van Hoof more than expected).
Fields of papers citing papers by A Van Hoof
This network shows the impact of papers produced by A Van Hoof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A Van Hoof. The network helps show where A Van Hoof may publish in the future.
Co-authors
The 25 scholars most cited alongside A Van Hoof, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2004 | 116 | |
| 2 | 1977 | 23 | |
| 3 | 1981 | 18 | |
| 4 | Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie. | 1997 | 16 |
| 5 | 2015 | 14 | |
| 6 | 1987 | 14 | |
| 7 | 1997 | 7 | |
| 8 | Cerebral venous thrombosis in paroxysmal nocturnal haemoglobinuria. | 1987 | 7 |
| 9 | Involved field irradiation (IFRT) does not improve outcome in patients with stage III/IV Hodgkin's lymphoma (HL) in complete remission after MOPP/ABV (M/A): Results of the randomised EORTC trial 20884 | 2001 | 6 |
About A Van Hoof
A Van Hoof is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Pathology and Forensic Medicine, Oncology and Hematology, having authored 9 papers that have together received 221 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (2 papers), Chronic Myeloid Leukemia Treatments (2 papers), Lymphoma Diagnosis and Treatment (2 papers), Lung Cancer Research Studies (1 paper), Liver Disease and Transplantation (1 paper), Mast cells and histamine (1 paper), Hemoglobinopathies and Related Disorders (1 paper) and Retinoids in leukemia and cellular processes (1 paper). The work is most often cited by research in Rheumatology (115 citations), Hematology (59 citations), Genetics (46 citations), Pulmonary and Respiratory Medicine (66 citations) and Immunology (41 citations). A Van Hoof has collaborated with scholars based in Belgium, Netherlands and Italy. Frequent co-authors include Peter Vandenberghe, Danny Vanstraelen, Marie Maerevoet, A Hagemeijer, Peter Marynen, Lucienne Michaux, Jan Cools, D. Gary Gilliland, Pierre Zachée and Dominik Selleslag. Their work appears in journals such as Annals of Oncology, Leukemia, Blood, Molecular Cancer and Journal of Cardiovascular Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.